Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
The latest announcement is out from Elite Pharmaceuticals ( (ELTP) ).
Elite Pharmaceuticals, Inc., a Northvale, N.J.-based specialty generics producer known for oral controlled-release drugs, will report financial results for the first quarter of its 2027 fiscal year, which ended June 30, 2026, on Thursday, August 13, 2026. The company distributes its portfolio of generic products nationwide under the Elite Laboratories label through its cGMP and DEA-registered facility.
Management plans to host a live conference call on Friday, August 14, 2026, at 11:30 a.m. EDT to discuss the quarter’s financial and operating performance and provide a broader corporate update. The planned disclosures and discussion are expected to give shareholders and other stakeholders greater transparency into Elite’s current business trajectory and operational progress within the competitive niche generics market.
Spark’s Take on ELTP Stock
According to Spark, TipRanks’ AI Analyst, ELTP is a Outperform.
Overall score reflects strong fundamentals and a reinforced growth narrative from the latest earnings call (record revenue, large operating income and cash flow gains, and low leverage). The score is tempered by historical volatility in profits/cash flow and a neutral technical setup with price still below the 200-day moving average; valuation is supportive with a low P/E.
To see Spark’s full report on ELTP stock,
click here.
More about Elite Pharmaceuticals
Elite Pharmaceuticals, Inc., traded on the OTCQB as ELTP, is a specialty pharmaceutical company focused on developing and distributing niche generic drug products. The company specializes in oral, controlled-release formulations and markets multiple generic products nationwide under the Elite Laboratories, Inc. label, supported by a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, New Jersey.
Elite’s operations center on leveraging its controlled-release technologies and regulatory-compliant infrastructure to serve the U.S. generic pharmaceuticals market. By maintaining its own manufacturing and development capabilities, the company seeks to strengthen its position within the niche generics segment and support ongoing product distribution and pipeline advancement across its therapeutic portfolio.
Average Trading Volume: 569,749
Technical Sentiment Signal: Hold
Current Market Cap: $388.9M
For detailed information about ELTP stock, go to TipRanks’ Stock Analysis page.